Evolus (EOLS) Short term Debt (2017 - 2020)
Evolus (EOLS) reported Short term Debt of $74.4 million for Q4 2020, up 2.4% quarter-over-quarter from $72.6 million in Q4 2017.
Evolus (EOLS) Short term Debt (2017 - 2020) Analysis & Trends
Evolus has reported Short term Debt for 2 years, with the latest figure at $74.4 million in Q4 2020.
- For the quarter ending Q4 2020, Short term Debt changed N/A year-over-year to $74.4 million; the trailing twelve-month figure through Dec 2020 stood at $74.4 million (changed N/A YoY), and the FY2020 full-year result was $74.4 million, changed N/A from the prior year.
- Short term Debt for Q4 2020 stood at $74.4 million, up from $72.6 million in the prior quarter.
- The five-year high for Short term Debt was $74.4 million in Q4 2020, with the low at $72.6 million in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn |
| 10 | Evolus | 435.45 Mn | 385.65 Mn | 48.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 74.38 Mn |
| Dec 31, 2017 | 72.64 Mn |